← 產業報告目錄
Neoantigen Cancer Vaccine Market Size, Share & Trends Analysis Report By Product (Personalized and Off-The-Shelf Neoantigen Vaccines), By Neovaccine Type, By Therapeutic Area, By Therapy Type, Region And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-23頁數 180報告編號 INSIGHTACE-751a78c9b8
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Neoantigen Cancer Vaccine Market is positioned for steady expansion, with a projected CAGR of 20.0% from 2025 to 2034.
Neoantigen Cancer Vaccine encompasses vaccines that assist in boosting the immune system by using a single or several antigens. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Several factors contribute to this trajectory, including heightened interest in next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region set to deliver the strongest growth trajectory through the forecast period, driven by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neoantigen Cancer Vaccine Market Snapshot
Chapter 4. Global Neoantigen Cancer Vaccine Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Global Neoantigen Cancer Vaccine Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Neoantigen Cancer Vaccine Market Industry Trends
Chapter 5. Neoantigen Cancer Vaccine Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Personalized Neoantigens vaccines
5.2.2. Off-the-shelf Neoantigen vaccines
Chapter 6. Neoantigen Cancer Vaccine Market Segmentation 2: By Neovaccine Type, Estimates & Trend Analysis
6.1. Market Share by Neovaccine Type, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Neovaccine Type:
6.2.1. Nucleic acid/DNA/mRNA Vaccine
6.2.2. Peptide Vaccines
6.2.3. Dendritic Cell–based Vaccines
Chapter 7. Neoantigen Cancer Vaccine Market Segmentation 3: By Therapy Type, Estimates & Trend Analysis
7.1. Market Share by Therapy Type, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapy Type:
7.2.1. Mono Therapeutic Regimens
7.2.2. Combinatorial Regimens
Chapter 8. Neoantigen Cancer Vaccine Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Neoantigen Cancer Vaccine Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.2.3. North America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034
8.2.4. North America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
8.3. Europe
8.3.1. Europe Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.3.3. Europe Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034
8.3.4. Europe Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.4.3. Asia Pacific Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034
8.4.4. Asia Pacific Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts By Therapy Type, 2021-2034
8.5. Latin America
8.5.1. Latin America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.5.3. Latin America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034
8.5.4. Latin America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.6.3. Middle East & Africa Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034
8.6.4. Middle East & Africa Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Roche
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Medimmune
9.2.3. Moderna Therapeutics/Merck
9.2.4. Advaxis
9.2.5. Agenus
9.2.6. Genocea Biosciences Inc
9.2.7. Gritstone Oncology
9.2.8. Neon Therapeutics
9.2.9. Nouscom
9.2.10. OSE Immunotherapeutics
9.2.11. Immunovative Therapeutics
9.2.12. Medigene
9.2.13. Vaccibody
9.2.14. Brightpath Biotherapeutics
9.2.15. Geneos Therapeutics
9.2.16. Frame Therapeutics
9.2.17. Immunetune
9.2.18. NeoPhore
9.2.19. CureVac AG
9.2.20. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們